Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
-
161
-
162
-
163
20E repressed ILP-mediated cell membrane translocation of HaP60 and HaP110, dephosphorylated HaP60 and HaP110, and decreased their interaction.
Published 2021“…Green, HaP60 or HaP110; red, cell membrane stained with WGA; blue, nuclei stained with DAPI; merge, overlapped green, blue, and red fluorescence. Bar, 50 μm. <b>C.</b> Co-IP assay showed that 20E decreased the HaP60–HaP110 interaction and induced dephosphorylation in cells. …”
-
164
Data_Sheet_1_rdHSV-CA8 non-opioid analgesic gene therapy decreases somatosensory neuronal excitability by activating Kv7 voltage-gated potassium channels.docx
Published 2024“…These data demonstrate for the first time that vHCA8 produces Kv7 channel activation, which decreases neuronal excitability in nociceptors. This suppression of excitability may translate in vivo as non-opioid dependent behavioral- or clinical analgesia, if proven behaviorally and clinically.…”
-
165
-
166
Demographic of the study participants, urinary arsenic species and Th17 cells.
Published 2022Subjects: -
167
-
168
-
169
Demographic of the study participants, urinary arsenic species and IL-17A cytokine.
Published 2022Subjects: -
170
-
171
-
172
-
173
-
174
-
175
Inhibiting Gamma-secretase activity without interfering in Notch signaling: Decreasing the inflammatory response in patients with cutaneous leishmaniasis
Published 2020“….; *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.</p><p><b>Figure 3 - Non-selective gamma-secretase inhibitor (DAPT) decreases inflammatory-associated proteins production from CL patients in response to <i>Leishmania</i>antigens.…”
-
176
-
177
-
178
-
179
Image 9_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi...
Published 2025“…EC<sub>50</sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<sub>0−3d</sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”
-
180
Image 8_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi...
Published 2025“…EC<sub>50</sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<sub>0−3d</sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”